Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
INDIANAPOLIS, Feb. 19, 2016 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection, today announced that senior management will give a corporate presentation and update at two upcoming investor conferences:
- The RBC Capital Markets 2016 Global Healthcare Conference in New York, NY on Wednesday, February 24, 2016 at 2:35pm ET.
- Cowen and Company's 36th Annual Healthcare Conference in Boston, MA on Monday, March 7, 2016 at 4:00pm ET.
The presentations will be webcast live and may be accessed through a link on the Investor Relations page of the company's website at assemblybio.com. Archived versions of the webcasts will be available on the Assembly website for 90 days beginning several hours after the live presentations.
For more information about the RBC Capital Markets 2016 Global Healthcare Conference, click here. For more information about the Cowen and Co. 36th Annual Healthcare Conference, click here.
About Assembly Biosciences
Assembly Biosciences, Inc. is a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and novel approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection. Assembly’s team has significant experience in infectious disease drug discovery and development and has collectively helped bring more than 10 anti-infective products to the market. The company’s HBV-Cure Program is aimed at increasing cure rates and is advancing multiple drug candidates that address upstream and downstream viral targets in the HBV lifecycle for possible use in combination therapy. The company’s Microbiome Program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under cGMP conditions, and a patent pending delivery system, GEMICELTM, which allows for targeted oral delivery of live biologic and conventional therapies to the lower GI tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile infection. For more information, visit assemblybio.com.
Contacts Corporate: Assembly Biosciences, Inc. David Barrett 646-706-5208 [email protected] Media: BLL Partners LLC Barbara Lindheim 212-584-2276 [email protected]
